---
title: Separate Parkinson from similar disorders
nct_id: NCT06490926
status: RECRUITING
sponsor: Fujian Medical University Union Hospital
study_type: OBSERVATIONAL
canonical_url: "https://parkinsonspathways.com/trial/NCT06490926"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT06490926"
last_fetched: "2026-05-10T14:08:34.116Z"
source: "Parkinson's Pathways (curated)"
---
# Separate Parkinson from similar disorders

**Goal (in five words):** Separate Parkinson from similar disorders

**Official Title:** NMR Based Metabolomic Study of Serum Biomarkers in Patients With Parkinson's Disease and Atypical Parkinsonian Syndrome

**Trial ID:** [NCT06490926](https://clinicaltrials.gov/study/NCT06490926)

## Key Facts

- **Status:** RECRUITING
- **Study Type:** OBSERVATIONAL
- **Sponsor:** Fujian Medical University Union Hospital
- **Target Enrollment:** 180 participants
- **Start Date:** 2023-02-01
- **Completion Date:** 2024-06-30
- **Conditions:** Progressive Supranuclear Palsy, Multiple System Atrophy, Parkinson's Disease

## Summary For Families

The goal is to find serum metabolic biomarkers that can reliably tell Parkinson's disease apart from atypical parkinsonian syndromes like multiple system atrophy and progressive supranuclear palsy, and to see whether subtypes such as MSA-P versus MSA-C or tremor-predominant versus PIGD Parkinson's have distinct metabolic fingerprints. The approach uses NMR spectroscopy on blood serum to measure many small-molecule metabolites, creating a noninvasive metabolic profile that could become a diagnostic fingerprint, and it is purely observational so it does not change your medications or interact with levodopa. Eligible participants are adults 45 to 80 years old with diagnoses of idiopathic Parkinson's disease, MSA, or PSP by standard criteria, while people with hereditary or secondary parkinsonism, prior deep brain stimulation, or a history of cancer are excluded.

## Eligibility

- **Minimum age:** 45 Years
- **Maximum age:** 80 Years
- **Sex:** ALL

### Full Criteria

```
Inclusion Criteria:

* 1\) MSA and PSP inclusion criteria

  * Age range from 45 to 80 years old;

    1. MSA inclusion criteria
  * Age range from 45 to 80 years old;

    * Meets the Chinese expert consensus on the diagnostic criteria for multiple system atrophy (2017) or the International Society for Parkinson\'s Disease and Movement Disorders (MDS) diagnostic criteria for multiple system atrophy (2022)

      ③ MSA subtype grouping: MSA is divided into MSA-P and MSA-C subtypes based on the severity of initial and/or motor symptoms, with Patients with Parkinson\'s syndrome as the main type are MSA-P, while patients with cerebellar syndrome as the main type are MSA-C.

      (2) PSP inclusion criteria
  * Age range from 45 to 80 years old;

    ② PSP patients who meet the diagnostic criteria for progressive supranuclear palsy in China (2016) or the diagnostic criteria for progressive supranuclear palsy in the International Society for Parkinson\'s Disease and Movement Disorders (MDS) (2017)

    (3) Selection criteria for Parkinson\'s disease case group
  * Age range from 45 to 80 years old;

    * Patients with idiopathic Parkinson\'s disease who meet the diagnostic criteria of the International Committee on Motor Disorders (MDS) for Parkinson\'s disease (2015);

      * Classification criteria for subtypes of Parkinson\'s disease:

        1. Tremor predominant type: According to the MDS-UPDRS score, the ratio of average tremor score to average PIGD score is ≥ 1.15
        2. PIGD type: According to the MDS-UPDRS score, the ratio of average tremor score to average PIGD score is ≤ 0.9

           Exclusion Criteria:
* ① Hereditary Parkinson\'s syndrome, secondary Parkinson\'s syndrome.

  * After deep brain stimulation (DBS) surgery.

    * Have a history of malignant tumors.
```

## Locations (1)

- Fujian Medical University Union Hospital, Fuzhou, Fujian, China _(26.0614, 119.3061)_
  - Ying Chen associate chief physician — (CONTACT) — 13365910067 — 2320609050@qq.com

## Central Contacts

- Ying Chen associate chief physician, Master — (CONTACT) — 13365910067 — 2320609050@qq.com

---

*Canonical: https://parkinsonspathways.com/trial/NCT06490926*  
*HTML version: https://parkinsonspathways.com/trial/NCT06490926*  
*Source data: https://clinicaltrials.gov/study/NCT06490926*